Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the document. The company remains debt-free as of June 30, 2025, with a strong cash and liquid investment position of Rs. 791 crores. Management emphasizes maintaining a comfortable cash position to manage adverse situations and support business continuity. CAPEX planned for FY 2026 is Rs. 400-Rs. 450 crores, funded internally from cash resources. There is no indication of raising fresh debt or equity in the near term. The focus appears to be on organic growth and prudent cash management without additi

Future growth expectations in earnings/operating earnings/profits/EPS?

Sharda Cropchem Limited expects revenue growth of around 15% for FY 2026. EBITDA margin guidance is maintained in the range of 15% to 18%, with a possibility to touch the higher side. Gross margins are expected to sustain at around 35%-36% for the full year, driven by stable business conditions and favorable forex movements. PAT grew 424% YoY in Q1 FY26, supported by strong revenue and margin expansion. The company is investing in registrations and planned CAPEX of Rs. 400-450 crores to support future growth. No adverse inventory impacts or order cancellations anticipated, implying business st

Current/ Expected Orderbook/ Pending Orders?

As of 30th June 2025, Sharda Cropchem has 2,981 registrations. Additionally, there are 1,021 applications for product registrations at the approval stage. There was no specific mention of the current or expected order book value or pending orders in the Q1 FY26 earnings call transcript. The company indicated strong registration pipeline and continued pursuit of registrations once initiated, unless regulatory bans occur. The management did not elaborate quantitatively on pending orders or order backlog during the call.

Future growth expectations in sales/revenue/volumes?

Sharda Cropchem Limited expects FY 2026 revenue growth of around 15%. In Q1 FY 2026, revenue grew 25% year-on-year to Rs. 985 crores, with overall volume growth of 13%. Agrochemical segment volume grew 11%, while non-agrochemical segment volume grew 59% year-on-year. The company maintains a robust registration pipeline with over 1,000 product registrations pending approval, supporting future growth. CAPEX planned at Rs. 400-450 crores for the year to support product registrations and expansion. European region, a major contributor, showed strong sales growth of 43% in revenues. Pri

IN US

Sale is live|00:00:00left today

Sharda Cropchem LtdQ2 FY25Fertilizers & Agrochemicals

Sharda Cropchem Ltd Q2 FY25 Earnings Call Analysis

Q: Any current/future capex/capital investment/strategic investment?

CAPEX for Q1 FY26 stood at Rs. 114 crores. Planned CAPEX for the full year FY26 is Rs. 400-Rs. 450 crores. The company aims to increase product registrations backed by this CAPEX. No significant strategic changes reported in registration pipeline strategy, continuing with the existing registrations unless products get banned. The company is focused on running business comfortably and maintaining liquidity to withstand any adverse situations. Dividend payouts have been liberalized recently, with two dividends declared in the last quarter. Overall, the company is investing heavily towards regis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹877P/E: 12.8Market Cap: ₹8.7K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Sharda Cropchem Limited expects FY 2026 revenue growth of around 15%.
→In Q1 FY 2026, revenue grew 25% year-on-year to Rs. 985 crores, with overall volume growth of 13%.
→Agrochemical segment volume grew 11%, while non-agrochemical segment volume grew 59% year-on-year.
→The company maintains a robust registration pipeline with over 1,000 product registrations pending approval, supporting future growth.
→CAPEX planned at Rs. 400-450 crores for the year to support product registrations and expansion.
→European region, a major contributor, showed strong sales growth of 43% in revenues.
→Pricing improvements are slow but steady, supporting margin and revenue growth.
→No major pre-stocking or destocking seen; demand growth is driven by genuine market demand.
→The management does not foresee disruption in growth due to tariffs or geopolitical issues, maintaining steady business operations.

Margin guidance

Category 3

→Sharda Cropchem Limited expects revenue growth of around 15% for FY 2026.
→EBITDA margin guidance is maintained in the range of 15% to 18%, with a possibility to touch the higher side.
→Gross margins are expected to sustain at around 35%-36% for the full year, driven by stable business conditions and favorable forex movements.
→PAT grew 424% YoY in Q1 FY26, supported by strong revenue and margin expansion.
→The company is investing in registrations and planned CAPEX of Rs. 400-450 crores to support future growth.
→No adverse inventory impacts or order cancellations anticipated, implying business stability.
→Currency exchange benefits, especially from Euro appreciation, are contributing positively.
→Management is optimistic about steady price improvements and strong demand on the ground rather than inventory restocking.
→With strong cash reserves and disciplined working capital management, the company is well-positioned for sustained profitability growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the document.
→The company remains debt-free as of June 30, 2025, with a strong cash and liquid investment position of Rs. 791 crores.
→Management emphasizes maintaining a comfortable cash position to manage adverse situations and support business continuity.
→CAPEX planned for FY 2026 is Rs. 400-Rs. 450 crores, funded internally from cash resources.
→There is no indication of raising fresh debt or equity in the near term.
→The focus appears to be on organic growth and prudent cash management without additional fundraising.

Order book

→As of 30th June 2025, Sharda Cropchem has 2,981 registrations.
→Additionally, there are 1,021 applications for product registrations at the approval stage.
→There was no specific mention of the current or expected order book value or pending orders in the Q1 FY26 earnings call transcript.
→The company indicated strong registration pipeline and continued pursuit of registrations once initiated, unless regulatory bans occur.
→The management did not elaborate quantitatively on pending orders or order backlog during the call.

Capex plans

Yes

- CAPEX for Q1 FY26 stood at Rs. 114 crores. - Planned CAPEX for the full year FY26 is Rs. 400-Rs. 450 crores. - The company aims to increase product registrations backed by this CAPEX. - No significant strategic changes reported in registration pipeline strategy, continuing with the existing registrations unless products get banned. - The company is focused on running business comfortably and maintaining liquidity to withstand any adverse situations. - Dividend payouts have been liberalized recently, with two dividends declared in the last quarter. Overall, the company is investing heavily towards registrations and growth with a strong CAPEX plan while maintaining healthy liquidity and shareholder rewards.

How does Sharda Cropchem Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Sharda Cropchem Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Sharda Cropchem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio